How is acute myeloid leukemia (AML) with genetic markers for favorable-risk disease treated?

Updated: Dec 17, 2018
  • Author: Ari VanderWalde, MD, MPH, MA, FACP; Chief Editor: Karl S Roth, MD  more...
  • Print
Answer

Answer

Tailoring conventional therapy to risk level, rather than targeting single mutations, is slightly more complicated and subjective. As in all diseases, the decision of which agents to use in AML depends on many factors, including functional status and age of the patient, determination of whether the cancer is secondary to previous cancer therapy or is an abnormal clone secondary to other hematologic disorders such as myelodysplastic syndrome, and the agents and resources available to the treating physician.

Patients with favorable-risk disease (ie, those with t(8;21) or inv(16)) tend to have low relapse rates following consolidation with high-dose cytarabine. Autologous or allogeneic stem cell transplants in these situations should be reserved for patients who have relapsed disease. [8]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!